Edition:
United States

Kala Pharmaceuticals Inc (KALA.OQ)

KALA.OQ on NASDAQ Stock Exchange Global Select Market

13.30USD
15 Jun 2018
Change (% chg)

$-0.42 (-3.06%)
Prev Close
$13.72
Open
$13.63
Day's High
$13.82
Day's Low
$13.08
Volume
99,782
Avg. Vol
55,503
52-wk High
$26.74
52-wk Low
$11.81

Chart for

About

Kala Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of therapeutics through its nanoparticle-based Mucus Penetrating Particles, or MPP, technology. The Company’s initial focus is on the treatment of eye diseases. The Company’s product candidate includes KPI-121 1%, KPI-121... (more)

Overall

Beta: --
Market Cap(Mil.): $326.68
Shares Outstanding(Mil.): 24.56
Dividend: --
Yield (%): --

Financials

  KALA.OQ Industry Sector
P/E (TTM): -- 240.92 34.18
EPS (TTM): -3.10 -- --
ROI: -66.89 -5.87 13.17
ROE: -- -7.71 15.15

BRIEF-Kala Pharmaceuticals Reports Q1 Loss Per Share Of $0.46

* KALA PHARMACEUTICALS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS

May 10 2018

BRIEF-Kala Pharmaceuticals - PDUFA Target Action Date For Inveltys Is August 24, 2018

* KALA PHARMACEUTICALS INC - PDUFA TARGET ACTION DATE FOR INVELTYS IS AUGUST 24, 2018 Source text for Eikon: Further company coverage:

May 09 2018

BRIEF-Kala Pharmaceuticals Posts Q4 Loss Per Share $0.46

* KALA PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS

Mar 26 2018

BRIEF-Kala Pharma Says Increased Size Of Board From 9 To 10

* KALA PHARMACEUTICALS - ‍ ON FEB 28, INCREASED SIZE OF BOARD FROM 9 TO 10 DIRECTORS; APPOINTED GREGORY PERRY AS DIRECTOR - SEC FILING​ Source text: (http://bit.ly/2oULmga) Further company coverage:

Mar 05 2018

BRIEF-Kala Appoints Gregory Perry To Board And As Audit Committee Chair

* KALA PHARMACEUTICALS APPOINTS GREGORY PERRY TO BOARD OF DIRECTORS AND AS AUDIT COMMITTEE CHAIR Source text for Eikon: Further company coverage:

Mar 05 2018

BRIEF-Orbimed Advisors Reports About 11 Pct Passive Stake In Kala Pharmaceuticals

* ORBIMED ADVISORS LLC REPORTS ABOUT 11 PERCENT PASSIVE STAKE IN KALA PHARMACEUTICALS INC AS OF JAN 10 Source text: (http://bit.ly/2DaEc0a) Further company coverage:

Jan 12 2018

Future of Kala Pharma's dry eye drug uncertain after mixed results

Mixed results from two late-stage studies testing Kala Pharmaceuticals Inc's drug to provide temporary relief from dry eye disease cast doubt on the drug's path forward and sent shares down 16 percent in early trading on Friday.

Jan 05 2018

UPDATE 2-Future of Kala Pharma's dry eye drug uncertain after mixed results

* Peak sales could hit $1.9 bln in 2027 - analyst (Recasts lede, updates shares, adds analyst comments)

Jan 05 2018

REFILE-Kala Pharma posts mixed results from dry eye disease drug studies

Jan 5 Kala Pharmaceuticals Inc on Friday reported mixed results from two late-stage trials testing its drug to provide temporary relief from the signs and symptoms of dry eye disease.

Jan 05 2018

BRIEF-Kala Pharmaceuticals Announces NDA For Inveltystm Accepted By U.S. FDA

* KALA PHARMACEUTICALS ANNOUNCES NEW DRUG APPLICATION FOR INVELTYSTM (KPI-121 1%) HAS BEEN ACCEPTED FOR REVIEW BY THE U.S. FOOD AND DRUG ADMINISTRATION

Jan 05 2018

Earnings vs. Estimates